Sarah H. Plummer - Concepedia

Author

Sarah H. Plummer

National Institute of Allergy and Infectious Diseases

Also Known As

Hope DeCederfelt, I Gordon, Lesia Dropulic, Lesia K. Dropulic, Olga Trofymenko, S. Plummer, Sarah H Plummer, Sarah H. Plummer, Sarah Plummer

Publications

4.2K

Citations

H-Index

Concepts

All Affiliations

National Institute of Allergy and Infectious Diseases National Institutes of Health Walter Reed Army Institute of Research University of Maryland, Baltimore University of California San Diego

About

Sarah H. Plummer is an author at National Institute of Allergy and Infectious Diseases specializing in medicine, immunology, and vaccination.

Top Concepts

#	Concept	H-Index	Publications	Citations
1	Medicine	12	12	2.3K
2	Immunology	11	11	2.1K
3	Immunotherapy	5	5	799
4	Pharmacology	2	2	140
5	Immunodominance	1	1	768

Sarah H. Plummer

Publications

3.6K

Citations

H-Index

Page 1

	Year	Citations
Protection Against Malaria by Intravenous Immunization with a Nonreplicating Sporozoite Vaccine Robert A. Seder, Lee-Jah Chang, Mary E. Enama, Science Pfspz VaccineMalariaImmunologyImmunodominancePlasmodium Falciparum	2013	768
Virologic effects of broadly neutralizing antibody VRC01 administration during chronic HIV-1 infection Rebecca M. Lynch, Eli Boritz, Emily E. Coates, Science Translational Medicine Hiv-1 Cd4Human RetrovirusPassive ImmunizationImmunologyAntiviral Response	2015	454
Protection against malaria at 1 year and immune correlates following PfSPZ vaccination Andrew S. Ishizuka, Kirsten E. Lyke, Adam DeZure, Nature Medicine VaccinationPfspz VaccinationVaccine TargetMalariaImmunology	2016	368
Safety, tolerability, and immunogenicity of two Zika virus DNA vaccine candidates in healthy adults: randomised, open-label, phase 1 clinical trials Martin R. Gaudinski, Katherine V. Houser, Kaitlyn M. Morabito, The Lancet	2017	298
Safety and pharmacokinetics of the Fc-modified HIV-1 human monoclonal antibody VRC01LS: A Phase 1 open-label clinical trial in healthy adults Martin R. Gaudinski, Emily E. Coates, Katherine V. Houser, PLoS Medicine	2018	249
Safety and tolerability of chikungunya virus-like particle vaccine in healthy adults: a phase 1 dose-escalation trial Lee-Jah Chang, Kimberly A. Dowd, Floreliz Mendoza, The Lancet VaccinationVaccine SafetyVaccine DevelopmentVaccine TargetVirology	2014	245
Attenuated PfSPZ Vaccine induces strain-transcending T cells and durable protection against heterologous controlled human malaria infection Kirsten E. Lyke, Andrew S. Ishizuka, Andrea A. Berry, Proceedings of the National Academy of Sciences	2017	245
Safety and Immunogenicity of DNA Vaccines Encoding Ebolavirus and Marburgvirus Wild-Type Glycoproteins in a Phase I Clinical Trial Uzma Sarwar, Pamela Costner, Mary E. Enama, The Journal of Infectious Diseases	2014	131
Safety, tolerability, pharmacokinetics, and immunogenicity of the therapeutic monoclonal antibody mAb114 targeting Ebola virus glycoprotein (VRC 608): an open-label phase 1 study Martin R. Gaudinski, Emily E. Coates, Laura Novik, The Lancet VaccinationOpen-label Phase 1Vaccine TargetImmunologyAntiviral Drug Development	2019	123
Low-Dose Subcutaneous or Intravenous Monoclonal Antibody to Prevent Malaria Richard L Wu, Azza H. Idris, Nina M. Berkowitz, New England Journal of Medicine	2022	114

Page 1